Sign in
Taking people in United StatesPhase 2

Artesunate added to standard treatment for cytomegalovirus infection after organ transplant

Tests artesunate plus ganciclovir or valganciclovir in organ transplant recipients with cytomegalovirus infection.

Key facts

Who runs it
Amivas Inc.
Where
Boston and Rochester, United StatesSee the 2 sitesAlso in 1 other country, 2 sites
Trial code
Registry title
Study Evaluating the Efficacy and Safety of Artesunate
Status
Recruiting
Phase
Phase 2
People taking part
90 people, planned
Started
1 Aug 2025
Expected to end
30 Jun 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Artesunate
  • Ganciclovir (GCV)
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a kidney, lung, heart or liver transplant who have a CMV infection needing treatment. It tests artesunate added to GCV or VGCV.

Age
18 years and older
Sex
All sexes can join
Disease stage
Documented CMV infection with CMV DNA in the blood (CMV DNAemia) that needs IV GCV or oral VGCV. Life expectancy of at least 12 weeks.
Earlier treatment
People must have stopped any anti-CMV antiviral drugs before joining (washout). People who took IV GCV or oral VGC daily for more than 8 days cannot join.
Biomarker or test result
CMV DNAemia (CMV DNA found in the blood)

Main reasons for not taking part

  • CMV infection or disease that has not responded to treatment (refractory), or CMV resistant to antiviral drugs
  • Known allergy to artesunate, GCV or VGCV
  • Pregnant, planning pregnancy, or breastfeeding
  • Severe liver disease
  • Need for drugs that interact with artesunate or GCV, or taking another study drug against CMV

This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: * Recipient of a solid organ transplant (kidney, lung, heart, or liver)

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Be at least 18 years of age
  • Recipient of a solid organ transplant (kidney, lung, heart, or liver)
  • Have a documented CMV infection
  • Have CMV DNAemia
  • Require IV GCV or oral VGCV
  • Be washed out from any anti-CMV antiviral drugs
  • Have all the following results as part of screening laboratory assessments
  • Have life expectancy of ≥ 12 weeks
  • Be willing and have an understanding and ability to fully comply with the study
  • If female use birth control

Who cannot take part

  • Have CMV antiviral drug resistance
  • Require ongoing treatment with or an anticipated need for treatment with drugs with known interactions with artesunate or GCV
  • Taking any another investigational drug with anti-CMV activity
  • Have refractory CMV infection or disease
  • Have a known hypersensitivity to artesunate, GCV, or VGCV
  • Have severe liver disease
  • Have taken IV GCV or oral VGC daily for >8 days
  • Pregnant (or expecting to conceive) or nursing

Where in United States

Also in 1 other country, 2 sites

  • Massachusetts General HospitalBoston, United StatesContact: Jaqueline Ferreira, BSTaking people
  • Mayo ClinicRochester, United StatesContact: Adam MillerTaking people

About the trial

What the trial wants to find out

This study is a randomized, open-label, active comparator-controlled, dose-ranging trial of the efficacy and safety of IV artesunate in combination with IV GCV or oral VGCV and SOC treatment compared to GCV or VGCV monotherapy and SOC treatment in SOT recipients with clinically significant CMV infection.

The 3 groups in the trial

  • Low Dose ArtesunateTreatment being tested

    Low Dose Artesunate: 2.4 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices

    Treatment: Artesunate

  • High Dose ArtesunateTreatment being tested

    High Dose Artesunate: 4.8 mg/kg IV artesunate once daily for 14 days + GCV or VGCV and SOC per local institutional practices

    Treatment: Artesunate

  • Standard Treatment GanciclovirExisting treatment, for comparison

    Standard Treatment Ganciclovir: GCV or VGCV and SOC per local institutional practices

    Treatment: Ganciclovir (GCV)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Phase 2, Randomized, Open-label, Active Comparator, Dose-ranging Study Evaluating the Efficacy and Safety of Artesunate for Injection in Combination With Ganciclovir or Valganciclovir for the Treatment of Cytomegalovirus Infection in Solid Organ Transplant Recipients
Plain-language title
Artesunate added to standard treatment for cytomegalovirus infection after organ transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
3 August 2026